Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 26, 2017
Pharmacy Choice - News - Generic Drugs - September 26, 2017

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 232     Next >>     Go To Page:

9/19/17 - GLENMARK MAY FILE 25 PRODUCT APPLICATIONS/YEAR
Glenmark Pharmaceuticals Limited of Mumbai is planning to file 25 abbreviated new drug applications per year till 2022.
9/18/17 - Fosun to acquire Gland Pharma, with smaller stake [China Daily: Africa Weekly]
Shanghai Fosun Pharmaceutical Group announced on Monday it will acquire an approximately 74 percent stake in the Indian generic drug maker Gland Pharma, down from the 86 percent stake announced last July. Fosun Pharmaceuticals will pay about $1.09 billion for the acquisition. It is the first injectable drugs manufacturer in India to be approved by
9/18/17 - Genentech Receives Blow by FDA in Cancer Drug Avastin Biosimilar Battle, an Industrial Info News Alert
Researched by Annette Kreuger, Industrial Info Resources Biological drug maker Genentech, the developer of the blockbuster cancer drug Avastin, was dealt a stunning blow on September 14 when the U.S. Food and Drug Administration approved a biosimilar. For details, view the entire article by subscribing to Industrial Info's Premium Industry News
9/18/17 - Generic Drugs Market is Anticipated to Show Growth by 2022
ReportsMonitor.com has added a new report to its database The Future of Generic Drugs and Strategies for Commercial Success Summary: GBI Research's latest report "The Future of Generic Drugs and Strategies for Commercial Success&a...
9/18/17 - Glancy Prongay & Murray LLP Continues Investigation on Behalf of Teva Pharmaceutical Industries Ltd. Investors
By a News Reporter-Staff News Editor at Pharma Business Week Glancy Prongay& Murray LLP continues its investigation on behalf of Teva Pharmaceutical Industries Ltd. investors concerning the Company and its officers' possible violations of federal securities laws. On August 2, 2016, Teva finalized its acquisition of Allergan plc's generics busines
9/18/17 - Inventiva's IVA337 Given Generic Name Lanifibranorby the World Health Organization (WHO)
Inventiva, a biopharmaceutical company developing innovative breakthrough therapies, particularly for the treatment of fibrotic diseases, today announced that the World Health Organization has granted it the international non-proprietary name lanifibranor for IVA337, its leading drug candidate, currently is in Phase IIb development for both...
9/18/17 - New Initiative Creates Scalable Solutions to Improve Care of Patients With Multiple Chronic Conditions
The initiative was announced to an audience of public health leaders at the World Economic Forum's Sustainable Development Impact Summit. TEVA Pharmaceutical Industries Ltd., the world's largest generic drug company, and Mount Sinai Health System, one of the largest hospital groups in the United States, aim to gain new data and insights into interv
9/18/17 - Perrigo Announces Tentative FDA Approval For The Generic Version Of Acanya Gel
Perrigo Company plc today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Acanya topical gel 1.2%/ 2.5%. Perrigo previously settled litigation with Dow Pharmaceutical Sciences, Inc. and Valeant Pharmaceuticals North America LLC for this product. Perrigo Company plc, a leading g
9/18/17 - RedHawk Pharma Agrees to Complete Marketing and Operational Joint Venture Agreement
RedHawk Holdings Corp. announced today that RedHawk Pharma UK Ltd, a wholly-owned subsidiary of RedHawk, has agreed in principle to enter into definitive marketing and operational joint venture agreements with ICE Pharma Group, a United Kingdom- based generic pharmaceutical sales and compliance company. RedHawk Pharma currently owns 75% of EcoGen
9/18/17 - Reports Summarize Biosimilars Study Results from Division of Rheumatology (Consensus-based recommendations for the use of biosimilars to treat...
Reports Summarize Biosimilars Study Results from Division of Rheumatology. The news reporters obtained a quote from the research from the Division of Rheumatology, "Four key topics regarding biosimilars were identified through a process of discussion and consensus. Relevant English-language publications through November 2016 were searched...
9/18/17 - Study Data from University of Massachusetts Provide New Insights into Adverse Drug Reactions (An Algorithm to Identify Generic Drugs in the FDA...
Study Data from University of Massachusetts Provide New Insights into Adverse Drug Reactions. According to news reporting out of Worcester, Massachusetts, by NewsRx editors, research stated, "Although generic drugs constitute approximately 88% of drugs prescribed in the US, there are no reliable methods to identify generic drugs in the US FDA Adver
9/18/17 - Teligent, Inc. Appoints Thomas J. Sabatino, Jr. to Board of Directors
Teligent, Inc., a New Jersey- based specialty generic pharmaceutical company, today announced it has appointed Thomas J. Sabatino, Jr. to its Board of Directors. Mr. Sabatino will also serve on the Company s Audit Committee.. His extensive experience in the various aspects of the pharmaceutical industry, including experience in manufacturing,
9/16/17 - A Biosimilar Cure for Sky-High Cancer Drug Prices [All Iraq News Agency (AIN)]
On Thursday, the U.S. Food and Drug Administration approved Amgen Inc. and Allergan PLC`s Mvasi, the first biosimilar to a cancer drug to win the regulatory green light. A 16- milliliter vial of Avastin can cost $2,854, according to the U.S. government`s Federal Supply Schedule. Generic drugs have been winning market share away from brand-name, sma
9/16/17 - Amgen and Allergan win FDA nod for biosimilar of Avastin, Roche`s $3B seller [Arab Finance (Egypt)]
The FDA has ushered in a new era in lower cost cancer medicines with its approval of Amgens and Allergan`s Mvasi, a biosimilar of Roches blockbuster drug Avastin. The FDA decision also issues in a new era for Roche, as Amgen and partner Allergan will work to capture as much of the $3 billion in sales the drug raked in from the U.S. last year. That
9/16/17 - Amgen Gains FDA Approval for Avastin Biosimilar [Sudan Tribune]
The U.S. Food and Drug Administration today approved Mvasi as a biosimilar to Avastin for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer. Bringing new biosimilars to patients, especially for diseases where the cost of existing treatments can be high, is an important way to h
9/16/17 - GSK fightback in lung drugs boosted by three-in-one inhaler endorsement [T-break Tech (Middle East)]
GSKs fightback in respiratory drugs has been given a boost after its novel three-in-one inhaler was recommended for approval in Europe. The FTSE 100 drugmakers sales in the crowded lung drugs market are under pressure, with its biggest-selling medicine Advair losing ground to generic rivals. Generic versions have been cleared for use in Europe, but
9/16/17 - US approves its first cancer biosimilar, India has several already [Arab News (Saudi Arabia)]
The United States of America is now for the first time getting a taste of a locally approved biosimilar drug for treating cancer. The regulator has approved Mvasi as a biosimilar to Avastin- Innovator company Roche- for the treatment of multiple types of cancer. For good or for bad, depending on who is viewing it, India has taken a lead here and go
9/15/17 - Determination That CORTONE (Cortisone Acetate) Tablets and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as they meet relevant legal and regulatory requirements. The 1984 amendments include what is now section 505 of
9/15/17 - Determination That TIMOPTIC (Timolol Maleate Ophthalmic Solution), 0.25 Percent and 0.5 Percent, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements. The 1984 amendments include what is now section 505 of th
9/15/17 - FDA approves first biosimilar for the treatment of cancer
Mvasi, a biosimilar to the cancer drug Avastin, is approved for certain colorectal, lung, brain, kidney and cervical cancers?
9/15/17 - Federal Register Extracts
This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as they meet relevant legal and regulatory requirements. The 1984 amendments include what is now section 505 of
9/15/17 - Merck Expands Celonic's Upstream Capabilities with Mobius Single use Bioreactors
Release date- 14092017- Merck, a leading science and technology company, today announced that Celonic AG, a Swiss contract development and manufacturing organization, is upgrading its manufacturing facility with five of Merck's Mobius single use bioreactors. Celonic, which produces biosimilars and also offers a cell line development platform, will
9/15/17 - Merck Expands Celonic's Upstream Capabilities with Mobius Single-use Bioreactors
Release date- 14092017- Darmstadt, Germany- Merck, a leading science and technology company, today announced that Celonic AG, a Swiss contract development and manufacturing organization, is upgrading its manufacturing facility with five of Merck's Mobius single use bioreactors. Celonic, which produces biosimilars and also offers a cell line develop
9/15/17 - Merck Expands Celonic's Upstream Capabilities with Mobius? Single-use Bioreactors - Press Release issued by Merck [Pakistan Press International]
Merck, a leading science and technology company, today announced that Celonic AG, a Swiss contract development and manufacturing organization, is upgrading its manufacturing facility with five of Merck's Mobius? single-use bioreactors. Celonic, which produces biosimilars and also offers a cell line development platform, will add 50-, 200- and 2
9/15/17 - Mylan blasts Allergan`s `desperate` tribal licensing deal on Restasis [Syrian Arab News Agency]
Now, the generic giant is dishing out barbs of its own, blasting Allergan for a new licensing deal with the Saint Regis Mohawk Tribe thats designed to shield eye drug Restasis from competition. Allergan unveiled the licensing deal on Friday, announcing the transfer of Restasis patents to the Saint Regis Mohawk Tribe in New York. The tribe will rece
Articles(s): 1 - 25 of 232     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415